ClinicalTrials.gg
RecruitingNCT06903546Updated Apr 3, 2025

The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients

A Phase 4 interventional study of Propolis drops and Placebo in Diabetes Mellitus Type 2, sponsored by Indonesia University. Recruiting at 1 site in Indonesia. Open to participants aged 35 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Indonesia University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
35 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Diabetes Mellitus, Type 2 by Indonesia University — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Indonesia University.

Planned enrollment
5th of 12
64 · median 55
Started
2025
with 1 other
Phase 4
2 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 35 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if propolis administration works to change the level of Low Density Lipoprotein (LDL) and High Density Lipoprotein cholesterol (HDL) in diabetic type 2 patients.

The main questions it aims to answer are:

  • Is giving 1 drops/ 10kg/ times, twice daily for 8 weeks will change the level of LDL and HDL level in diabetic type 2 patients compared to placebo? Researchers will compare propolis to a placebo (a look-alike substance that contains no drug) to see if propolis works to change LDL and HDL cholesterol level.

Participants will:

  • Take propolis or a placebo, 2 times daily with given dose (1 drops/10 kg/times) every day for 2 months
  • Visit the sub-district health centre once every 2 weeks for checkups
  • Get their blood checked before and after intervention
Read the detailed description

Subject allocation into groups will be made by third party to ensure masking/ blinding protocol.

Data that will be taken from participants :

  • Private information
  • Medication history (for type 2 Diabetes Mellitus)
  • Food intake (calories, fats, carbohydrate, protein, and flavonoid intake)
  • Physical activity status
03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Propolis
  • Diabetes Mellitus Type 2
  • Low Density Lipoprotein
  • High Density Lipoprotein
04

Who can participate

Ages eligible
35 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Controlled Diabetes Mellitus type 2 with \<7.5%
  • 23-35 kg/m2
  • On anti-cholesterol therapy

Exclusion criteria

Exclusion Criteria:

  • Using injection therapy (insulin or GLP-1 RA)
  • History of bees product allergy
  • Active smoker
  • Consuming alcohol
  • Altered liver (>35 IU/L) and kidney (\<90 mL/min) function
  • Pregnant and breastfeeding women
  • History of cardiovascular disease (heart attack, stroke)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Intervention group

    This group will receive the intervention, which in this study is propolis with dose given 1 drop/kg/time given, 2 times daily, for 8 weeks (2 months)

    Drug: Propolis drops

  • Placebo comparator
    Control group

    This group will receive placebo (a look-alike substance that contains no drug) with dose given 1 drop/kg/time given, 2 times daily, for 8 weeks (2 months)

    Other: Placebo

Interventions

  • DrugPropolisStudies of PropolisPropolis pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention given is propolis drops that are approved by Indonesian Food and Drug Authority

  • OtherPlacebo

    The given placebo are look-alike substance with no effect

06

What researchers measure

Primary outcomes

  1. Low Density Lipoprotein

    LDL level will be measured twice, before and after intervention

    Time frame: 8 weeks

  2. High Density Lipoprotein

    HDL will be measured twice, before and after intervention

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Indonesia Faculty of Biomedical Science
    Jakarta, 10430, Indonesia
    Recruiting
08

References and documents

Publications

  • Zakerkish M, Jenabi M, Zaeemzadeh N, Hemmati AA, Neisi N. The Effect of Iranian Propolis on Glucose Metabolism, Lipid Profile, Insulin Resistance, Renal Function and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial. Sci Rep. 2019 May 13;9(1):7289. doi: 10.1038/s41598-019-43838-8. PubMed 31086222 ↗
  • Samadi N, Mozaffari-Khosravi H, Rahmanian M, Askarishahi M. Effects of bee propolis supplementation on glycemic control, lipid profile and insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial. J Integr Med. 2017 Mar;15(2):124-134. doi: 10.1016/S2095-4964(17)60315-7. PubMed 28285617 ↗

Individual participant data

Plan to share: No — Confidentiality issue

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2025, 3 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 3 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Mar 30, 2025
StartActual
Mar 18, 2025
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jul 31, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06903546
Responsible party
Dr. drg. Dwirini Retno Gunarti, M.S. (Associate Professor, Indonesia University) — Principal investigator
First posted
Mar 30, 2025
Start date
Mar 18, 2025
Primary completion
Jun 30, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Apr 3, 2025

Study contacts

Dwirini R Gunarti, Biomed Science
Contact
rinairet@gmail.com
+62 8118382301
Wiryani Sentosa, MD
Contact
wiryani@ymail.com
+62 81210977847
Dwirini R Gunarti, Biomed Science
principal investigator · Indonesia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propolis

Start the discussion